The extract is made using a unique encapsulation technology called Techcare that protects saffron from alterations
French ingredient specialist Activ'Inside has revealed its saffron stigma extract has obtained a new patent in the US.
Issued on 28 February 2023 by the US patent office, the patent protects the composition and dosage of safranal in the encapsulated saffron extract. Activ’Inside has also secured patents for its saffron extract in Europe, Malaysia, and South Africa.
The extract is made using a unique encapsulation technology called Techcare that protects saffron from alterations and preserves its native composition to ensure a full spectrum product.
Speaking about the approval, Activ’Inside’s CEO Benoit Lemaire said: ““Obtaining this patent is a new official recognition of the high added value of Safr'Inside, our encapsulated saffron extract featuring a very high safranal content: 0.2% [as measured] by HPLC.”
According to Activ’Inside, the company has conducted seven studies, including in vivo, ex-vivo, and clinical studies, that have demonstrated the ability of Safr’Inside to modulate serotonin, pointing to its potential impact on stress, sleep, menopause, premenstrual syndrome, and digestion; all of which serotonin is involved in.
Further studies are underway, amounting to $3.5 million investment.